To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) retreatment regimen in patients affected by neovascular age-related macular degeneration
BACKGROUND AND OBJECTIVE: To evaluate the proportion of patients achieving a 12-week (q12) afliberce...
Treating neovascular age-related macular degeneration (nAMD) with intravitreal aflibercept (IVT-AFL)...
Introduction: AZURE was a 76-week, randomized, open-label, parallel-group, phase IIIb noninferiority...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascu...
Purpose To determine efficacy and safety of intravitreal aflibercept in patients with neovascular ag...
Aim: To determine real life clinical outcomes in poorly responsive and treatment-naïve neovascular a...
Purpose To determine efficacy and safety of intravitreal aflibercept in patients with neovascular ag...
Arshad M Khanani Sierra Eye Associates, Reno, NV, USA Purpose: To evaluate the durability of fixed...
BACKGROUND AND OBJECTIVE: To evaluate the proportion of patients achieving a 12-week (q12) afliberce...
PURPOSE To investigate outcomes in patients with neovascular age-related macular degeneration (AM...
BACKGROUND AND OBJECTIVE: To evaluate the proportion of patients achieving a 12-week (q12) afliberce...
Treating neovascular age-related macular degeneration (nAMD) with intravitreal aflibercept (IVT-AFL)...
Introduction: AZURE was a 76-week, randomized, open-label, parallel-group, phase IIIb noninferiority...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) ...
Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascu...
Purpose To determine efficacy and safety of intravitreal aflibercept in patients with neovascular ag...
Aim: To determine real life clinical outcomes in poorly responsive and treatment-naïve neovascular a...
Purpose To determine efficacy and safety of intravitreal aflibercept in patients with neovascular ag...
Arshad M Khanani Sierra Eye Associates, Reno, NV, USA Purpose: To evaluate the durability of fixed...
BACKGROUND AND OBJECTIVE: To evaluate the proportion of patients achieving a 12-week (q12) afliberce...
PURPOSE To investigate outcomes in patients with neovascular age-related macular degeneration (AM...
BACKGROUND AND OBJECTIVE: To evaluate the proportion of patients achieving a 12-week (q12) afliberce...
Treating neovascular age-related macular degeneration (nAMD) with intravitreal aflibercept (IVT-AFL)...
Introduction: AZURE was a 76-week, randomized, open-label, parallel-group, phase IIIb noninferiority...
DOI
Add to ORKG